DAVID SALO, Appellant, υ. LINDA TYLER, KAVISH CHOUDHARY, and JOHN VU, Appellees.
No. 20150520
SUPREME COURT OF THE STATE OF UTAH
February 22, 2018
2018 UT 7
Third District, Salt Lake. The Honorable Richard D. McKelvie. No. 120905443. On Direct Appeal.
Attorneys:
Sean N. Egan, Salt Lake City, for appellant
Sean D. Reyes, Att‘y Gen., Joshua D. Davidson, Asst. Att‘y Gen., Salt Lake City, for appellees
ASSOCIATE CHIEF JUSTICE LEE authored the opinion of the Court, in which CHIEF JUSTICE DURRANT, JUSTICE HIMONAS, JUDGE BROWN, and JUDGE HYDE joined.
Having recused himself, JUSTICE PEARCE does not participate herein; DISTRICT COURT JUDGE JENNIFER A. BROWN sat.
Due to her retirement, JUSTICE DURHAM did not participate herein; DISTRICT COURT JUDGE NOEL S. HYDE sat.
JUSTICE PETERSEN became a member of the Court on November 17, 2017, after oral argument in this matter, and accordingly did not participate.
¶ 1 In 2011 David Salo was fired from Amgen, Inc., where he worked as a pharmaceutical representative. Salo later filed claims for defamation and interference with economic relations, asserting that three administrators at the University of Utah Hospital pharmacy—Linda Tyler, Kavish Choudhary, and John Vu—defamed him and caused him to lose his job. The district court dismissed these claims on summary judgment. We affirm.
¶ 2 In so doing we first clarify the operative summary judgment standard under
¶ 3 We affirm summary judgment under this standard. We hold that the defendants were entitled to summary judgment under the
¶ 4 We also affirm the district court‘s decision to refuse to strike an affidavit submitted by Linda Tyler in support of the motion
I
¶ 5 In 2011 David Salo was working as a pharmaceutical representative for Amgen, Inc. His largest account was with the University of Utah Hospital system. He worked particularly closely with the Huntsman Cancer Hospital. Salo was also a member of the Medical Service Representatives Committee (MSR) at the hospital. In that volunteer capacity he helped coordinate the relationship between pharmaceutical companies such as Amgen, their drug representatives, and hospital administrators and staff.
¶ 6 On April 27, 2011, a nurse at the university hospital contacted Salo about a patient who suffered from bony-metastatic disease and giant cell tumor (GCT). The nurse reached out to Salo on behalf of Dr. Lance Gouw, a physician in the University of Utah hospital system. Dr. Gouw had developed a plan to treat the patient‘s GCT, a plan that included the use of denosumab, a drug manufactured by Amgen. Since the U.S. Food and Drug Administration (FDA) had not approved denosumab for treatment of GCT, Dr. Gouw‘s nurse inquired whether Salo had any information on treating GCT with the drug. Salo had never heard of GCT before and told the nurse he would get back to her. He also directed her to Amgen Medical Information for more information. Later Dr. Gouw‘s physician assistant Grace Noda followed up with Salo. Salo gave Noda the contact information of a doctor from MD Anderson Cancer Center who had experience using denosumab for GCT.
¶ 7 At the same meeting, Noda asked Salo about Amgen‘s patient assistance programs administered through the Amgen Foundation. The patient in question did not have commercial health insurance and thus was not eligible for the First Step Program. But Salo did provide information about Amgen‘s other program, the Safety Net Program, designed for patients without insurance. Dr. Gouw later applied to the program on behalf of his patient.
¶ 9 Vu reported this conversation to Choudhary, writing about “perceived” off-label promotion of denosumab by Salo. Vu relayed that the “action of giving out the MD Anderson physician info would likely be considered off-label promotion.” Choudhary also heard from the hospital‘s pharmacy director, who reported that certain hospital staff were under the impression that Salo had given Dr. Gouw Amgen‘s financial assistance debit cards for use for an off-label treatment. Choudhary forwarded this information to Tyler.
¶ 10 Tyler assigned Choudhary to lead the pharmacy‘s investigation into the matter, and Vu, as Salo‘s MSR liaison, was assigned to assist Choudhary. Choudhary and Vu delegated some fact-finding responsibilities to the clinical supervisor, Dan Sageser. Soon after Choudhary began his investigation, he instructed Sageser to file a complaint against Salo with the FDA.
¶ 11 Salo reported his interactions with Dr. Gouw‘s staff to Amgen compliance on April 28, 2011. The company later opened its own internal investigation into Salo‘s actions. In the course of this investigation, Amgen contacted Choudhary to set up a meeting, and he and Vu met with Amgen compliance officers on June 1, 2011, and June 6, 2011. In these meetings Choudhary and Vu repeated the accusations against Salo—that he had improperly promoted an off-label treatment by passing on the information of a physician who had experience using denosumab off-label and that he had improperly given Noda information about Amgen‘s patient assistance programs to pay for these off-label treatments.
¶ 12 Amgen terminated Salo following its internal investigation. The company made the decision on July 29, 2011. It alerted Salo on August 18, 2011. The company cited four grounds for termination: Salo contacted Amgen Medical Affairs on behalf of the hospital rather than referring hospital staff directly to Amgen; Salo referred Noda to a third-party physician who had experience with off-label use of denosumab; Salo provided patient financial assistance
¶ 13 Shortly before Salo found out about his termination, he contacted Senator Mike Lee‘s office. In response to an inquiry from Senator Lee‘s office, Tyler wrote an email on August 8, 2011, to eleven administrators at the university—administrators directly involved in the investigation or high-level officials who would benefit from knowledge of the situation as they might need to field questions from Senator Lee‘s office.
¶ 14 Ray Lynch, executive director of the hospital, responded to Tyler‘s email. Tyler replied on August 10, 2011, copying two other administrators. Her email to Lynch described FDA regulations “that state that a company can‘t market a drug for off-label use.” She also noted that using patient assistance programs for off-label use “is not in the best interest of our patients or the organization.”
¶ 15 Salo filed claims against Choudhary and Vu for defaming him during their two June meetings with Amgen compliance officials and for interfering with his employment with Amgen. He also filed against Tyler for defamation and interference with economic relations relating to her two emails to university administrators.
¶ 16 After discovery Tyler—and later Choudhary and Vu—filed motions for summary judgment. Salo opposed these motions. He also moved to strike an affidavit that Choudhary and Vu submitted in support of their motion—the affidavit of Linda Tyler. In Salo‘s view this affidavit was improper because Tyler had not been identified as a witness under
¶ 17 The district court granted the motions for summary judgment and denied the motion to strike. In denying the motion to strike the district court concluded there was no harm or prejudice to Salo. It concluded that Choudhary and Vu had “been abundantly diligent in making disclosures” and that Salo had a “full opportunity” to depose Tyler and to question the basis for the information contained in Tyler‘s affidavit.
¶ 18 In granting the motions for summary judgment the district court concluded that the defendants were entitled to immunity under the
¶ 19 Salo challenges the entry of summary judgment and the denial of the motion to strike. We review the summary judgment decision de novo. See Bahr v. Imus, 2011 UT 19, ¶ 16, 250 P.3d 56. We review the denial of the motion to strike under an abuse of discretion standard. See Murdock v. Springville Mun. Corp., 1999 UT 39, ¶ 25, 982 P.2d 65.
II
¶ 20 Salo challenges both the decision granting defendants’ motion for summary judgment and the decision denying his motion to strike. We affirm for reasons explained below.
A
¶ 21 Salo advances three grounds for challenging the decision granting summary judgment under the Governmental Immunity Act. He argues: (1) that the district court erred in assigning to him the burden of coming forward with evidence in response to a motion for summary judgment; (2) that there is a genuine issue of material fact as to whether Choudhary and Vu were acting within the scope of their employment; and (3) that there is a genuine issue of material fact as to the willfulness of the defendants’ misconduct. We find none of these points persuasive.
1
¶ 22 Salo questions the summary judgment standard applied by the district court. Citing Orvis v. Johnson, 2008 UT 2, 177 P.3d 600, he insists that the moving party always bears the burden of coming
¶ 23 Salo‘s position has an apparent foothold in dicta in Orvis. There we admittedly stated that “Utah law does not allow a summary judgment movant to merely point out a lack of evidence in the nonmoving party‘s case, but instead requires a movant to affirmatively provide factual evidence establishing that there is no genuine issue of material fact.” Orvis, 2008 UT 2, ¶ 16. And in so stating we purported to distance ourselves from the federal standard set forth in Celotex Corp. v. Catrett, 477 U.S. 317 (1986)—the U.S. Supreme Court decision holding that a moving party may carry its burden of persuasion on summary judgment without producing its own affirmative evidence if the nonmoving party bears the burden of persuasion at trial and the moving party “demonstrate[s] the absence of a genuine issue of material fact.” Id. at 323; see Orvis, 2008 UT 2, ¶ 16 (noting that although Celotex “has been the law in the federal courts for over two decades now, it is not Utah law,” and expressly “declin[ing] to adopt the reasoning of the Celotex decision“).
¶ 24 These statements were unnecessary to our decision in Orvis, however, because the moving party in Orvis was seeking summary judgment “on the merits of his own claim,” 2008 UT 2, ¶ 14—a claim on which he would bear the burden of persuasion at trial. Everyone agrees that a moving party bears a burden of coming forward with evidence on matters on which the movant bears the burden at trial. See Celotex, 477 U.S. at 323 (noting that a party cannot succeed on a claim without making “a sufficient showing” on elements on which it “has the burden of proof“). And for that reason the disavowal of Celotex was not relevant to the decision in Orvis.
¶ 25 The Orvis opinion, moreover, is not entirely consistent on the question of the moving party‘s burden. Despite its disavowal of Celotex and its apparent adoption of a rule requiring the moving party to “affirmatively provide factual evidence establishing that there is no genuine issue of material fact,” the Orvis court proceeded to articulate a standard that seems to mirror Celotex precisely:
A summary judgment movant, on an issue where the nonmoving party will bear the burden of proof at trial, may satisfy its burden on summary judgment by showing, by reference to “the pleadings, depositions, answers to interrogatories, and admissions on file,
together with the affidavits, if any,” that there is no genuine issue of material fact.
UTAH R. CIV. P. 56(c) . Upon such a showing, whether or not supported by additional affirmative factual evidence, the burden then shifts to the nonmoving party, who “may not rest upon the mere allegations or denials of the pleadings,” but “must set forth specific facts showing that there is a genuine issue for trial.”Id. (e) .
¶ 26 This is essentially the Celotex standard. It says that the extent of the moving party‘s burden varies depending on who bears the burden of persuasion at trial. A movant who seeks summary judgment on a claim on which it will bear the burden of persuasion at trial cannot seek summary judgment without producing affirmative evidence in support of the essential elements of its claim. But a movant who seeks summary judgment on a claim on which the nonmoving party bears the burden of persuasion may show that there is no genuine issue of material fact without producing its own evidence.
¶ 27 Our recent cases have attributed this standard to Orvis. See, e.g., Jones v. Trevor Mktg., Inc. v. Lowry, 2012 UT 39, ¶ 30, 284 P.3d 630 (citing Orvis as establishing the above-quoted standard). We have even stated that “our summary judgment jurisprudence regarding burden shifting” is “entirely consistent with Celotex.” Id. ¶ 30 n.9. Yet we have never fully embraced Celotex. We have clung, perhaps confusingly, to the notion that our Utah summary judgment standard is somehow distinct from that set forth in Celotex. See id. (asserting that “we have not adopted Celotex in its entirety“).
¶ 28 We now repudiate that notion. We hold that our Utah summary judgment standard is in line with the federal standard set forth in Celotex.
¶ 29 We do so because we find the Celotex standard entirely compatible with the terms and conditions of our rules of civil procedure. See
¶ 30 This follows not just from the terms and structure of
¶ 31 The summary judgment standard anticipates—and mirrors—the directed verdict inquiry. If a defendant can show that the plaintiff has no legally sufficient evidentiary basis for its claims at trial, the defendant may establish the lack of a genuine issue of material fact and an entitlement to judgment as a matter of law. And a defendant may make that showing without adducing any affirmative evidence of its own.
¶ 32 This is the federal standard as stated in Celotex. And we now embrace it without reservation as completely consistent with our Utah Rules of Civil Procedure.
¶ 33 We also reject Salo‘s threshold argument on appeal. We conclude that the district court did not err in its statement of the operative standard for summary judgment. Salo is the plaintiff in this case. As plaintiff he bears the burden of establishing the elements of his claims. Thus Tyler, Choudhary, and Vu bore the threshold burden of showing the absence of a genuine issue of material fact and of demonstrating their entitlement to judgment as a matter of law. But they may carry that burden without adducing
2
¶ 34 Salo also challenges the district court‘s determination that Choudhary and Vu acted within the scope of their employment in investigating his alleged misconduct. Quoting Newman v. White Water Whirlpool, 2008 UT 79, ¶ 10, 197 P.3d 654, Salo maintains that “scope of employment questions are inherently fact bound.” He also cites evidence that investigating off-label promotion was not part of Choudhary‘s or Vu‘s regular duties. And he asserts that this evidence creates a genuine issue of material fact, defeating defendants’ entitlement to judgment as a matter of law.
¶ 35 We disagree. The scope of employment standard is statutory. It comes from
¶ 36 The district court‘s approach was in line with the standard set forth in Birkner. An employee‘s action is within the scope of employment under Birkner if it is (1) “of the general kind the employee is employed to perform” and (2) “motivated, at least in part, by the purpose of serving the employer‘s interest.”4 Birkner, 771 P.2d at 1057. Thus, an employee acts within the scope of employment when her acts are “generally directed toward the accomplishment of objectives within the scope of the employee‘s duties and authority, or reasonably incidental thereto.” Id. The question is whether the worker is performing “duties assigned by the employer, as opposed to being wholly involved in a personal endeavor.” Id.
¶ 37 It is beside the point under this standard that investigating off-label promotion was not a “regular” duty for Choudhary and Vu—or, as Salo indicates, that “there were no policies or procedures to guide an investigation” of this sort. Regularity is not the question. And an employer need not have an established policy or procedure for everything within the scope of employment. All that matters is that the work is “of the general kind” assigned to the employee and
¶ 38 There is no genuine issue under the governing standard. This was not a rogue action by isolated employees. It was a coordinated hospital investigation. The hospital had a strong interest in investigating and resolving a matter that could lead to the imposition of sanctions by the FDA. And Tyler was acting appropriately in assigning someone within the hospital system to investigate the allegations against Salo. Choudhary and Vu, moreover, were acting under direction from their supervisors. They were protecting the interests of the hospital and performing “duties assigned by the employer“; in no sense were they “involved in a personal endeavor.” See id.
¶ 39 We affirm on this basis. We conclude that there was no genuine issue of material fact on the question of whether the defendants were acting within the scope of their employment. In so holding we clarify that the notion that a particular question may often be “fact bound,” see Newman, 2008 UT 79, ¶ 10, is no categorical barrier to its resolution on summary judgment. The relevant question is not whether a particular question generally or typically is susceptible to summary disposition; it is whether there is a genuine dispute of fact in an individual case as presented on the record before the court. Here we find that there is no genuine issue of material fact. And we affirm summary judgment despite the notion that scope of employment questions may often be subject to dispute.
3
¶ 40 Salo also claims that there is a genuine issue of material fact as to whether Tyler, Choudhary, and Vu engaged in willful misconduct. Here Salo points to evidence in the record that the defendants held ill will toward him and sought to injure him. And because Salo sees willfulness as turning on a defendant‘s state of mind, he contends that this matter should not have been resolved on summary judgment.
¶ 41 Willfulness, again, is a statutory construct. See
¶ 42 We affirm the entry of summary judgment under this standard. We conclude that the defendants were entitled to judgment as a matter of law because Salo failed to adduce evidence that the defendants intentionally engaged in any wrongful act.
¶ 43 Salo has charged defendants with two sets of wrongful acts—defamation and interference with economic relations. But the allegation of defamation is at the heart of both claims. The interference claim requires proof of wrongful interference. Eldridge v. Johndrow, 2015 UT 21, ¶ 70, 345 P.3d 553. And Salo‘s only assertion of wrongfulness is his allegation of defamatory statements. So both claims rise or fall on the basis of Salo‘s ability to establish not just a false, defamatory statement but an intentional one.
¶ 44 A defamatory statement is wrongful only if it is false. And defamation is intentional (and thus willful) only if the defendant had knowledge of its falsity. That means that Salo bears the burden of showing not just that the defendants made false, defamatory statements but that they did so with knowledge of falsity.
¶ 45 We affirm the entry of summary judgment because Salo has failed to carry his burden of producing such evidence. Much of the evidence cited by Salo goes to the defendants’ knowledge that their statements would likely cause Salo harm. But that is insufficient. To defeat summary judgment, Salo must do more than just show that the defendants knew their statements would harm him; he must present evidence that they knew their statements were false.
¶ 46 Salo points to two pieces of evidence in support of his assertion that the defendants knew that their statements were false. But neither of them is sufficient to defeat summary judgment.
¶ 47 First, Salo highlights a letter that Linda Tyler received from Dr. Gouw. The letter, sent and received before Tyler sent her allegedly defamatory emails, indicates Dr. Gouw‘s view that Salo “represented himself in a completely professional manner and never tried to promote the use of his products outside the authorized FDA indications.” Salo cites the letter in support of his view that the patient‘s “treatment was ordered based on Dr. Gouw‘s clinical judgment and not on advice or counsel of Mr. Salo.”
¶ 48 This letter, however, falls far short of showing that Tyler knew that the contents of her emails were false. Tyler‘s emails accused Salo of indirectly promoting off-label use by giving information to Dr. Gouw‘s staff about patient assistance. And the
¶ 49 Tyler‘s concerns about indirect promotion were rooted in a report from John Vu—a report suggesting that Salo had provided the information of an out-of-state physician who had used denosumab off-label. Tyler was concerned that this amounted to indirect promotion of an off-label use. And Dr. Gouw‘s letter does nothing to rebut this concern. If anything the letter seems to reinforce it. It states that “Mr. Salo also provided contact information for another specialist at MD Anderson Cancer Center to discuss their institutional experience with denosumab.”
¶ 50 The Gouw letter also reinforced another concern about Salo‘s indirect promotion—that he had provided information about Amgen‘s patient assistance programs while knowing that Dr. Gouw intended to use the drug off-label. Dr. Gouw wrote that “Mr. Salo provided information on First Step Program as well as about Safety Net” and that the “[a]pplication has been completed for assistance from Amgen.”
¶ 51 For these reasons the Gouw letter in no way shows that Tyler knew that the statements in her emails were false. That letter speaks only to Dr. Gouw‘s view that Salo had not engaged in direct promotion. And it reinforces a basis for Tyler‘s concerns about indirect promotion.
¶ 52 Salo also highlights a comment made by Kavish Choudhary to a colleague—a comment suggesting that Salo had been fired for being in the clinic areas and for harassing clinic staff. Choudhary had been informed earlier that Salo had never been in the clinic area, so in Salo‘s view Choudhary must have known that this statement was false. But Choudhary made the statement about Salo‘s firing months after Amgen terminated Salo. So the cited statement tells us nothing about whether Choudhary knew of the falsity of statements he made months earlier (at the time of Salo‘s termination). At most the cited statement could provide a basis for a determination that Choudhary had some sort of malice toward Salo. But again that is insufficient.
¶ 53 For these reasons we affirm the entry of summary judgment on the ground that Salo failed to produce evidence of willfulness. In so doing we also reject Salo‘s assertion that
B
¶ 54 Salo moved to strike the affidavit of Linda Tyler, submitted by Choudhary and Vu in support of their motion for summary judgment. The basis for challenging the affidavit was the failure of these defendants to identify Tyler as a witness in the final disclosure they submitted under
¶ 55 Salo challenges this decision as an abuse of discretion. He asserts that the district court could not rely on Tyler‘s affidavit because Choudhary and Vu failed to follow
¶ 56 Choudhary and Vu initially listed Tyler as a witness they expected to call at trial. But they dropped her from their
¶ 57 Salo also deposed Tyler. In the deposition Salo had every opportunity to inquire into all of the issues she testified to in her
¶ 58 We affirm on this basis. We hold that the district court acted well within its discretion in denying the motion to strike on the basis of a lack of prejudice.
III
¶ 59 The district court applied the correct summary judgment standard. It also properly determined that the defendants were entitled to judgment as a matter of law and that the motion to strike failed for a lack of prejudice.
